Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Management of acute kidney injury in the intensive care unit: a cost-effectiveness analysis of daily vs alternate-day hemodialysis.

Desai AA, Baras J, Berk BB, Nakajima A, Garber AM, Owens D, Chertow GM.

Arch Intern Med. 2008 Sep 8;168(16):1761-7. doi: 10.1001/archinte.168.16.1761.

PMID:
18779463
2.

Economic evaluation of sevelamer in patients with end-stage renal disease.

Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M.

Nephrol Dial Transplant. 2007 Oct;22(10):2867-78. Epub 2007 Jun 25.

PMID:
17595182
3.

Intensive care unit prognostic scoring systems to predict death: a cost-effectiveness analysis.

Glance LG, Osler T, Shinozaki T.

Crit Care Med. 1998 Nov;26(11):1842-9.

PMID:
9824077
4.

Cost of acute renal failure requiring dialysis in the intensive care unit: clinical and resource implications of renal recovery.

Manns B, Doig CJ, Lee H, Dean S, Tonelli M, Johnson D, Donaldson C.

Crit Care Med. 2003 Feb;31(2):449-55.

PMID:
12576950
5.

Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis.

Quinn RR, Naimark DM, Oliver MJ, Bayoumi AM.

Am J Kidney Dis. 2007 Sep;50(3):421-32.

PMID:
17720521
6.
7.

Intermittent hemodialysis versus continuous renal replacement therapy for acute renal failure in the intensive care unit: an observational outcomes analysis.

Rauf AA, Long KH, Gajic O, Anderson SS, Swaminathan L, Albright RC.

J Intensive Care Med. 2008 May-Jun;23(3):195-203. doi: 10.1177/0885066608315743.

PMID:
18474503
8.

Economics of dialysis dependence following renal replacement therapy for critically ill acute kidney injury patients.

Ethgen O, Schneider AG, Bagshaw SM, Bellomo R, Kellum JA.

Nephrol Dial Transplant. 2015 Jan;30(1):54-61. doi: 10.1093/ndt/gfu314. Epub 2014 Oct 17.

9.

Outcome comparisons of intermittent and continuous therapies in acute kidney injury: what do they mean?

Ronco C, Bagshaw SM, Gibney RT, Bellomo R.

Int J Artif Organs. 2008 Mar;31(3):213-20. Review.

PMID:
18373314
10.

Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.

Wagner M, Goetghebeur M, Merikle E, Pandya A, Chu P, Taylor DC.

Can J Clin Pharmacol. 2009 Summer;16(2):e331-45. Epub 2009 Jun 16.

PMID:
19531812
11.

When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature.

Talmor D, Shapiro N, Greenberg D, Stone PW, Neumann PJ.

Crit Care Med. 2006 Nov;34(11):2738-47. Review.

PMID:
16957636
12.
13.

Cost analysis of blood purification in intensive care units: continuous versus intermittent hemodiafiltration.

Vitale C, Bagnis C, Marangella M, Belloni G, Lupo M, Spina G, Bondonio P, Ramello A.

J Nephrol. 2003 Jul-Aug;16(4):572-9.

PMID:
14696761
15.

Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.

Earnshaw SR, Wilson MR, Dalal AA, Chambers MG, Jhingran P, Stanford R, Mapel DW.

Respir Med. 2009 Jan;103(1):12-21. doi: 10.1016/j.rmed.2008.10.005. Epub 2008 Nov 17.

16.
17.

The Hannover Dialysis Outcome study: comparison of standard versus intensified extended dialysis for treatment of patients with acute kidney injury in the intensive care unit.

Faulhaber-Walter R, Hafer C, Jahr N, Vahlbruch J, Hoy L, Haller H, Fliser D, Kielstein JT.

Nephrol Dial Transplant. 2009 Jul;24(7):2179-86. doi: 10.1093/ndt/gfp035. Epub 2009 Feb 13.

PMID:
19218540
18.

Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence.

Wu JM, Siddiqui NY, Amundsen CL, Myers ER, Havrilesky LJ, Visco AG.

J Urol. 2009 May;181(5):2181-6. doi: 10.1016/j.juro.2009.01.037. Epub 2009 Mar 17.

PMID:
19296983
19.

The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.

Roe RH, Lass JH, Brown GC, Brown MM.

Cornea. 2008 Oct;27(9):1001-7. doi: 10.1097/ICO.0b013e31817bb062.

PMID:
18812762
20.

Economic evaluation of continuous renal replacement therapy in acute renal failure.

Klarenbach S, Manns B, Pannu N, Clement FM, Wiebe N, Tonelli M; Alberta Kidney Disease Network..

Int J Technol Assess Health Care. 2009 Jul;25(3):331-8. doi: 10.1017/S0266462309990134.

PMID:
19619352

Supplemental Content

Support Center